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curve was observed when 2,5-DHA was studied. In the absence 
of tyrosinase, no inhibitory effect upon the enzyme could be 
observed. 
When tested against the B-16 melanoma in vivo by daily 
intraperitoneal injection at doses ranging from 10 to 75 mg/kg, 
there was no significant prolongation of survival observed with 
either 3,4-DHA or 2,5-DHA. At higher doses, significant toxicity 
was observed. 
DISCUSSION 
Melanoma cells possess a unique enzymatic apparatus for the 
conversion of levodopa to the pigment melanin. It has been 
suggested that it may be possible to take advantage of the very 
high intracellular oxidative potential associated with the mel-
anin pathway to design chemotherapeutic agents for melanoma 
[8-10]. 
Since the phenol L-glutamic acid y-4-hydroxyanilide (MHA) 
was reported [3] to be inhibitory to the growth of B-16 mela-
noma, it seemed reasonable to prepare more readily oxidizable 
analogs in order to enhance activity. Our studies support the 
concept that cytotoxicity is, indeed, related to ease of oxidation, 
since each of the dihydroxy analogs of MHA is more toxic than 
the parent phenol when administered in vivo. The 2,5-dihy-
droxy derivative particularly is also more cytotoxic in vitro, 
suggesting that para positioning of hydroxy groups leads to an 
increased effect. 
As reported earlier (3], the oxidation product of 3,4-DHA is 
a potent inhibitor of isolated DNA polymerase. Isomeric sub-
stitution of hydroxy groups in the 2,5-dihydroxy derivatives 
results in retention of the ability to inhibit DNA polymerase in 
the presence of tyrosinase. We have previously shown that 6-
hydroxydopa, an analog of levodopa, differs significantly from 
the latter in the pattern of macromolecular synthesis inhibition 
[ll]. A similar phenomenon is observed h ere, with the para 
derivative ·being less selective than the ortho. 
Several mechanisms of cytotoxicity have been proposed for 
catechols, including inhibition of DNA polymerase by quinone 
metabolites and the intracellular generation of free radicals [ll, 
12]. It may be that, depending on which isomeric arrangement 
of hydroxy groups is present, one of these mechanisms is 
preferred. 
At the present time, we do not have a definitive explanation 
for the marked host toxicity of 3,4-DHA and 2,5-DHA. One 
possibility that might be considered is cleavage of the y-gluta-
myl amide bond, which would release 3,4-dihydroxyaniline and 
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2,5-dihydroxyaniline respectively. 3,4-Dihydroxyaniline is 
chemically a very unstable species, and data regarding its 
toxicity are unavailable in the literature. On the other hand, 
Torigoe [3] has reported the single-dose LD50 of 2,5-dihydrox-
yaniline in rats to be 30 mg/ kg, and it seems very likely that 
the 3,4-dihydroxy compound would exhibit similar toxic prop-
erties. Perhaps, further chemical modification might result in 
increased stability of the amide bond and reduce systemic 
toxicity. 
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Correction 
In the October issue in the article "Ro 20-1724: An Agent that Significantly Improves Psoriatic Lesions 
in Double-Blind Clinical Trials" by Stawiski et a! (73:261-263) Table II (which appeared on page 262) 
was misprinted. The correct version of the table appears here. 
TABLE II. Clinical effects by drug concentration of Ro 20- 1724 on 
psoriasis" 
Number of test sites at each 
Concentrations of concentration 
Ro 20- 1724 
1% .5% .25% P lacebo 
Response 
2 11 11 8 0 
l 7 7 10 4 
0 0 0 0 14 
" Each of the nine patients tested in duplicate sites with the prepa-
rations above (see text). A possible dose response effect may be present 
at the 0.25% concentration. Response was graded as fo llows: no im-
provement = 0, minimal improvement = l, and moderate or better 
improvement = 2. 
